Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- REPL
- Price
- 7.35
- Stock movement up
- +0.43 (6.21%)
- Company name
- Replimune Group Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 565.63M
- Ent value
- 568.87M
- Price/Sales
- 139.94
- Price/Book
- 1.48
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 19.52%
- 1 year return
- 5.60%
- 3 year return
- -28.34%
- 5 year return
- -8.03%
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
REPL does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 139.94 |
| Price to Book | 1.48 |
| EV to Sales | 140.74 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 76.96M |
| EPS (TTM) | -2.71 |
| FCF per share (TTM) | -2.40 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 4.04M |
| Gross profit (TTM) | 1.95M |
| Operating income (TTM) | -231.58M |
| Net income (TTM) | -213.02M |
| EPS (TTM) | -2.71 |
| EPS (1y forward) | -3.03 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 48.27% |
| Operating margin (TTM) | -5729.32% |
| Profit margin (TTM) | -5270.21% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 113.49M |
| Net receivables | 832.00K |
| Total current assets | 442.63M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 64.59M |
| Total assets | 498.20M |
| Accounts payable | 8.41M |
| Short/Current long term debt | 76.12M |
| Total current liabilities | 43.79M |
| Total liabilities | 116.74M |
| Shareholder's equity | 381.46M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -181.09M |
| Capital expenditures (TTM) | 7.21M |
| Free cash flow (TTM) | -188.31M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -55.84% |
| Return on Assets | -42.76% |
| Return on Invested Capital | -49.43% |
| Cash Return on Invested Capital | -43.69% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 6.94 |
| Daily high | 7.36 |
| Daily low | 6.88 |
| Daily Volume | 765K |
| All-time high | 52.65 |
| 1y analyst estimate | 16.88 |
| Beta | 1.19 |
| EPS (TTM) | -2.71 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| REPL | S&P500 | |
| Current price drop from All-time high | -86.04% | -12.89% |
| Highest price drop | -90.48% | -56.47% |
| Date of highest drop | 29 May 2024 | 9 Mar 2009 |
| Avg drop from high | -50.34% | -11.07% |
| Avg time to new high | 51 days | 12 days |
| Max time to new high | 1096 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
565.63M
Marketcap category
Small-cap
Description
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Employees
331
Website
Investor relations
-
SEC filings
CEO
Philip Astley-Sparke
Country
USA
City
Woburn
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page